Literature DB >> 17116556

Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.

Rodrigo Gomes da Silva1, Paul H Sugarbaker.   

Abstract

BACKGROUND: Although lymph node and liver metastases are recognized as indications for resection of metastatic disease from colorectal cancer, carcinomatosis has not traditionally been regarded as having surgical treatment options. Reports have suggested that complete surgical removal of carcinomatosis combined with thorough irrigation of the peritoneal cavity with chemotherapy could result in longterm survival in selected patients. Proper selection factors are important because palliative surgery in these patients has not proved beneficial. STUDY
DESIGN: From a database of 156 patients with carcinomatosis from colorectal cancer, a retrospective analysis of data prospectively recorded in 70 patients with complete cytoreduction was performed. Eleven clinical and treatment factors were studied in univariate and multivariable analyses using survival as an end point.
RESULTS: By univariate analysis, patients with peritoneal cancer index (PCI) of<20 had a median survival of 41 months compared with 16 months for patients with PCI>20 (p=0.004). The difference in negative versus positive lymph nodes was also significant; differences in survival that were improved but not significant were present for age greater than 30 years, mucinous histology, location within the colon versus rectum, and absence of an adverse factor such as cancer perforation or obstruction present at the time of primary cancer resection. Only PCI<20 versus PCI>20 and lymph node status were significant in the multivariable analysis.
CONCLUSIONS: Favorable longterm results of complete cytoreduction in patients treated for carcinomatosis are associated with a limited volume of carcinomatosis observed at the time of cytoreduction and in patients with negative lymph nodes at the time of primary operation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116556     DOI: 10.1016/j.jamcollsurg.2006.08.024

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  78 in total

1.  Cytoreductive surgery and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colonic origin: outcomes after 7 years' experience of a new centre for peritoneal surface malignancies.

Authors:  Pedro Bretcha-Boix; Jose Farré-Alegre; Manuel Sureda; Carlos Dussan; Juan José Pérez Ruixo; Antonio Brugarolas Masllorens
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

Review 2.  Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Authors:  Hassan-Alaa-Hammed Al-Shammaa; Yan Li; Yutaka Yonemura
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

Review 3.  Surgical treatment of peritoneal carcinomatosis: current treatment modalities.

Authors:  Yakup Kulu; Beat Müller-Stich; Markus W Büchler; Alexis Ulrich
Journal:  Langenbecks Arch Surg       Date:  2013-11-19       Impact factor: 3.445

Review 4.  Oligometastatic Disease in the Peritoneal Space with Gastrointestinal Cancer.

Authors:  Beate Rau; Andreas Brandl; Andreas Pascher; Wieland Raue; Paul Sugarbaker
Journal:  Visc Med       Date:  2017-02-10

Review 5.  Peritoneal Metastases from Gastrointestinal Cancer.

Authors:  Paul H Sugarbaker
Journal:  Curr Oncol Rep       Date:  2018-06-08       Impact factor: 5.075

Review 6.  Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure.

Authors:  Loek A W de Jong; Fortuné M K Elekonawo; Philip R de Reuver; Andre J A Bremers; Johannes H W de Wilt; Frank G A Jansman; Rob Ter Heine; Nielka P van Erp
Journal:  Br J Clin Pharmacol       Date:  2018-10-25       Impact factor: 4.335

7.  Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: The University of Arizona early experience.

Authors:  Ioannis T Konstantinidis; Christine Young; Vassiliki L Tsikitis; Ellyn Lee; Tun Jie; Evan S Ong
Journal:  World J Gastrointest Surg       Date:  2012-06-27

8.  Prevention and Treatment of Peritoneal Metastases: a Comprehensive Review.

Authors:  Paul H Sugarbaker
Journal:  Indian J Surg Oncol       Date:  2019-01-03

9.  Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer.

Authors:  Konstantinos I Votanopoulos; Katrina Swett; Aaron U Blackham; Chukwuemeka Ihemelandu; Perry Shen; John H Stewart; Edward A Levine
Journal:  Ann Surg Oncol       Date:  2013-03-02       Impact factor: 5.344

10.  Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C.

Authors:  Laura A Lambert; Terri S Armstrong; J Jack Lee; Suyu Liu; Matthew H G Katz; Cathy Eng; Robert A Wolff; Melissa L Tortorice; Pier Tansey; Santiago Gonzalez-Moreno; Donald H Lambert; Paul F Mansfield
Journal:  Ann Surg Oncol       Date:  2009-05-28       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.